NBPF19

Summary

NBPF19 (NBPF member 19, HGNC:31999) is a protein-coding gene on chromosome 1q21.2, encoding NBPF family member NBPF19 (A0A087WUL8).

Predicted to be located in cytoplasm.

Source: NCBI Gene 101060226 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 1 total
• Phenotypes (HPO): 1
• MANE Select transcript: NM_001351365

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31999
Approved symbol	NBPF19
Name	NBPF member 19
Location	1q21.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000271383
Ensembl biotype	protein_coding
OMIM	614006
Entrez	101060226

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000651566

RefSeq mRNA: 1 — MANE Select: NM_001351365 NM_001351365

CCDS: CCDS86016

Canonical transcript exons

ENST00000651566 — 94 exons

Exon	Start	End
ENSE00003841219	149496789	149496897
ENSE00003841256	149526962	149527013
ENSE00003841447	149492768	149492940
ENSE00003841577	149540301	149540473
ENSE00003841635	149550667	149550718
ENSE00003841657	149522865	149523037
ENSE00003841795	149520575	149520683
ENSE00003841974	149475898	149476107
ENSE00003842161	149514936	149515108
ENSE00003842416	149545930	149545981
ENSE00003842559	149544300	149544408
ENSE00003842560	149531691	149531742
ENSE00003842572	149513356	149513528
ENSE00003842672	149498417	149498468
ENSE00003842952	149527614	149527786
ENSE00003843015	149534812	149534920
ENSE00003843085	149553774	149553882
ENSE00003843156	149539563	149539671
ENSE00003843363	149487332	149487383
ENSE00003843380	149508595	149508767
ENSE00003843594	149507939	149507990
ENSE00003843673	149547472	149547523
ENSE00003843676	149514238	149514289
ENSE00003843742	149495200	149495251
ENSE00003843774	149546590	149546762
ENSE00003843934	149554495	149556361
ENSE00003844030	149482175	149482226
ENSE00003844346	149545038	149545210
ENSE00003844384	149526070	149526242
ENSE00003844404	149551327	149551499
ENSE00003844474	149504716	149504767
ENSE00003844498	149503178	149503229
ENSE00003844731	149499955	149500006
ENSE00003844903	149538676	149538848
ENSE00003844951	149510179	149510351
ENSE00003845027	149541193	149541244
ENSE00003845124	149511808	149511980
ENSE00003845132	149524445	149524617
ENSE00003845154	149536446	149536497
ENSE00003845210	149549037	149549145
ENSE00003845349	149537982	149538033
ENSE00003845377	149512700	149512751
ENSE00003845425	149518992	149519043
ENSE00003845577	149500657	149500829
ENSE00003845644	149517456	149517507
ENSE00003845659	149491139	149491311
ENSE00003845690	149502286	149502458
ENSE00003845805	149497525	149497697
ENSE00003845892	149537100	149537272
ENSE00003845927	149492026	149492134
ENSE00003846079	149533925	149534097
ENSE00003846259	149530799	149530971
ENSE00003846600	149488013	149488185
ENSE00003846733	149477945	149478047
ENSE00003846758	149552887	149553059
ENSE00003846830	149493660	149493711
ENSE00003846842	149516564	149516736
ENSE00003846873	149511066	149511174
ENSE00003846891	149548150	149548322
ENSE00003846969	149478880	149479094
ENSE00003846992	149501544	149501652
ENSE00003847057	149529174	149529346
ENSE00003847188	149552209	149552260
ENSE00003847336	149518110	149518282
ENSE00003847725	149486130	149486293
ENSE00003847782	149503834	149504006
ENSE00003847810	149542735	149542786
ENSE00003847919	149507047	149507219
ENSE00003847960	149535554	149535726
ENSE00003848002	149480679	149480884
ENSE00003848381	149522211	149522262
ENSE00003848659	149549775	149549947
ENSE00003848775	149480142	149480214
ENSE00003848806	149505418	149505590
ENSE00003848875	149541853	149542025
ENSE00003848885	149475045	149475795
ENSE00003849147	149523747	149523798
ENSE00003849215	149499073	149499245
ENSE00003849290	149530061	149530169
ENSE00003849341	149488905	149488956
ENSE00003849369	149525332	149525440
ENSE00003849586	149509477	149509528
ENSE00003849668	149533227	149533278
ENSE00003849741	149495902	149496074
ENSE00003849774	149543413	149543585
ENSE00003849922	149490443	149490494
ENSE00003850127	149519688	149519860
ENSE00003850623	149489561	149489733
ENSE00003850733	149521319	149521491
ENSE00003850807	149494318	149494490
ENSE00003850858	149515822	149515930
ENSE00003851030	149528496	149528547
ENSE00003851085	149506305	149506413
ENSE00003851207	149532345	149532517

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 98.90.

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	98.90	gold quality
bone marrow cell	CL:0002092	97.48	gold quality
monocyte	CL:0000576	97.34	gold quality
leukocyte	CL:0000738	97.32	gold quality
colonic epithelium	UBERON:0000397	96.36	gold quality
ventricular zone	UBERON:0003053	96.22	gold quality
granulocyte	CL:0000094	96.16	gold quality
calcaneal tendon	UBERON:0003701	94.89	gold quality
tonsil	UBERON:0002372	94.03	gold quality
mucosa of stomach	UBERON:0001199	93.89	gold quality
stromal cell of endometrium	CL:0002255	93.69	gold quality
skin of abdomen	UBERON:0001416	92.65	gold quality
zone of skin	UBERON:0000014	92.40	gold quality
smooth muscle tissue	UBERON:0001135	92.32	gold quality
skin of leg	UBERON:0001511	92.02	gold quality
bone marrow	UBERON:0002371	91.89	gold quality
descending thoracic aorta	UBERON:0002345	91.74	gold quality
ganglionic eminence	UBERON:0004023	91.18	gold quality
vermiform appendix	UBERON:0001154	91.14	gold quality
blood	UBERON:0000178	90.87	gold quality
right coronary artery	UBERON:0001625	90.38	gold quality
urinary bladder	UBERON:0001255	90.15	gold quality
subcutaneous adipose tissue	UBERON:0002190	90.13	gold quality
fallopian tube	UBERON:0003889	90.11	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	90.02	gold quality
popliteal artery	UBERON:0002250	89.98	gold quality
tibial artery	UBERON:0007610	89.97	gold quality
endometrium	UBERON:0001295	89.95	gold quality
ovary	UBERON:0000992	89.94	gold quality
body of uterus	UBERON:0009853	89.62	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-GEOD-125970	yes	21.96
E-CURD-135	no	620.90
E-MTAB-7316	no	460.69
E-GEOD-150728	no	435.54
E-ANND-3	no	1.56

Regulation

Is transcription factor: no

Cross-species orthologs

0 orthologs

Paralogs (14): NBPF3 (ENSG00000142794), NBPF20 (ENSG00000162825), NBPF6 (ENSG00000186086), NBPF4 (ENSG00000196427), NBPF1 (ENSG00000219481), NBPF11 (ENSG00000263956), NBPF15 (ENSG00000266338), NBPF12 (ENSG00000268043), NBPF9 (ENSG00000269713), NBPF8 (ENSG00000270231), NBPF14 (ENSG00000270629), (ENSG00000271254), NBPF10 (ENSG00000271425), NBPF26 (ENSG00000273136)

Protein

Protein identifiers

NBPF family member NBPF19 — A0A087WUL8 (reviewed: A0A087WUL8)

Alternative names: Neuroblastoma breakpoint family member 19

All UniProt accessions (1): A0A087WUL8

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Cytoplasm.

Miscellaneous. Encoded by one of the numerous copies of NBPF genes clustered in the p36, p12 and q21 region of the chromosome 1.

Similarity. Belongs to the NBPF family.

RefSeq proteins (1): NP_001338294* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR010630	Olduvai_dom	Domain
IPR055306	NBPF	Family

Pfam: PF06758

UniProt features (79 total): domain 45, region of interest 16, compositionally biased region 16, chain 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

No AlphaFold model available for A0A087WUL8 — AlphaFold DB does not currently provide models for proteins above ~3000 aa.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 15 (showing top): chr1q21, KLF14_TARGET_GENES, KLF7_TARGET_GENES, ZNF10_TARGET_GENES, ZNF391_TARGET_GENES, ZNF423_TARGET_GENES, ZNF660_TARGET_GENES, ZNF843_TARGET_GENES, ZSCAN21_TARGET_GENES, ZSCAN30_TARGET_GENES, HU_FETAL_RETINA_RPE, ZNF579_TARGET_GENES, ZSCAN4_TARGET_GENES, INSM2_TARGET_GENES, PRDM4_TARGET_GENES

GO Biological Process (0):

GO Molecular Function (0):

GO Cellular Component (1): cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

218 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NBPF19	NOTCH2NLA	Q7Z3S9	667
NBPF19	OR4L1	Q8NH43	580
NBPF19	OR2T10	Q8NGZ9	571
NBPF19	LRP12	Q9Y561	546
NBPF19	NOTCH2NLB	P0DPK3	507
NBPF19	HHIPL2	Q6UWX4	447
NBPF19	NKAPL	Q5M9Q1	395
NBPF19	CFAP46	Q8IYW2	391
NBPF19	SCNN1D	P51172	348
NBPF19	NOL4L	Q96MY1	348
NBPF19	L1TD1	Q5T7N2	329
NBPF19	TRIM15	Q9C019	313
NBPF19	SMPD4	Q9NXE4	305
NBPF19	PI4K2A	Q9BTU6	278
NBPF19	MUC3A	Q02505	269

IntAct

0 interactions, top by confidence:

BioGRID (233): NBPF19 (Affinity Capture-RNA), NBPF19 (Two-hybrid), NBPF19 (Two-hybrid), NBPF19 (Two-hybrid), NBPF19 (Two-hybrid), NBPF19 (Two-hybrid), NBPF19 (Two-hybrid), NBPF19 (Two-hybrid), NBPF19 (Two-hybrid), NBPF19 (Two-hybrid), NBPF19 (Two-hybrid), NBPF19 (Two-hybrid), NBPF19 (Two-hybrid), NBPF19 (Two-hybrid), NBPF19 (Two-hybrid)

ESM2 similar proteins: A0A087WUL8, A0A0J9YWL9, A0A0U1RQI7, A0A1D9BZF0, A6NJU9, A6NKU9, A6NNC1, A6QL64, A8MRT5, B2SU53, B4DH59, B5DUH6, C9JG80, E5RHQ5, F8W0I5, P01068, P02895, P06916, P07907, P0DKL2, P0DPF3, P0DRJ4, P13208, P14417, P32072, P83060, Q26755, Q3BBV0, Q3BBV2, Q4ZJY7, Q4ZJZ0, Q4ZJZ1, Q4ZJZ3, Q5TAG4, Q5TI25, Q6P3W6, Q6RY98, Q7T3L1, Q86SG3, Q86T75

Diamond homologs: A0A087WUL8, B4DH59, P0C2Y1, P0DPF2, P0DPF3, Q32LC2, Q3BBV0, Q3BBV2, Q5TAG4, Q5TI25, Q5VU43, Q5VWK0, Q6P3W6, Q86T75, Q86XG9, Q8N660, Q96M43, Q9H094, A0A096LNW5, A2RUV0, G3I6Z6, O35516, P0DPK3, P0DPK4, P10040, P21783, P46530, P46531, Q01705, Q04721, Q04756, Q07008, Q20911, Q7Z3S9, Q80YT7, Q99466, Q9QW30, Q9UM47, Q19UN5, Q8K389

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

1 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	1
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2563 predictions. Top by Δscore:

Variant	Effect	Δscore
1:149475896:A:AG	acceptor_gain	1.0000
1:149475897:G:GG	acceptor_gain	1.0000
1:149475897:GTCC:G	acceptor_gain	1.0000
1:149475897:GTCCC:G	acceptor_gain	1.0000
1:149476103:ATACA:A	donor_gain	1.0000
1:149476108:G:GG	donor_gain	1.0000
1:149477943:A:AG	acceptor_gain	1.0000
1:149477944:G:GA	acceptor_gain	1.0000
1:149477944:GA:G	acceptor_gain	1.0000
1:149480136:TTACA:T	acceptor_loss	1.0000
1:149480138:ACAG:A	acceptor_loss	1.0000
1:149480139:CA:C	acceptor_loss	1.0000
1:149480140:A:AG	acceptor_gain	1.0000
1:149480140:AGAA:A	acceptor_loss	1.0000
1:149480141:G:GG	acceptor_gain	1.0000
1:149480141:G:GT	acceptor_loss	1.0000
1:149480141:GA:G	acceptor_gain	1.0000
1:149480141:GAA:G	acceptor_gain	1.0000
1:149480141:GAAA:G	acceptor_gain	1.0000
1:149480668:T:TA	acceptor_gain	1.0000
1:149482169:TTACA:T	acceptor_loss	1.0000
1:149482170:TACAG:T	acceptor_loss	1.0000
1:149482171:ACAG:A	acceptor_loss	1.0000
1:149482172:CA:C	acceptor_loss	1.0000
1:149482173:A:AC	acceptor_loss	1.0000
1:149482173:A:AG	acceptor_gain	1.0000
1:149482174:G:A	acceptor_loss	1.0000
1:149482174:G:GG	acceptor_gain	1.0000
1:149487383:GGT:G	donor_loss	1.0000
1:149487384:GT:G	donor_loss	1.0000

AlphaMissense

25003 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:149500811:T:C	F1037L	0.998
1:149500813:T:A	F1037L	0.998
1:149500813:T:G	F1037L	0.998
1:149510333:T:C	F1525L	0.996
1:149510335:T:A	F1525L	0.996
1:149510335:T:G	F1525L	0.996
1:149496056:T:C	F793L	0.994
1:149496058:T:A	F793L	0.994
1:149496058:T:G	F793L	0.994
1:149500812:T:C	F1037S	0.994
1:149491293:T:C	F549L	0.993
1:149491295:T:A	F549L	0.993
1:149491295:T:G	F549L	0.993
1:149500781:T:C	F1027L	0.993
1:149500783:T:A	F1027L	0.993
1:149500783:T:G	F1027L	0.993
1:149501577:G:T	R1054M	0.992
1:149510334:T:C	F1525S	0.992
1:149491294:T:C	F549S	0.991
1:149495963:T:C	C762R	0.991
1:149500818:T:C	L1039P	0.991
1:149506354:G:C	K1303N	0.991
1:149506354:G:T	K1303N	0.991
1:149510303:T:C	F1515L	0.991
1:149510305:T:A	F1515L	0.991
1:149510305:T:G	F1515L	0.991
1:149500818:T:A	L1039H	0.990
1:149501575:A:C	R1053S	0.990
1:149501575:A:T	R1053S	0.990
1:149496057:T:C	F793S	0.989

dbSNP variants (sampled 300 via entrez): RS1043866 (1:149556114 C>A,G), RS111884557 (1:149514755 T>A), RS112466911 (1:149509929 T>A), RS112542840 (1:149521084 C>G), RS112637520 (1:149525218 G>C), RS113072215 (1:149524185 G>A), RS113202683 (1:149531329 A>G), RS113249690 (1:149508837 A>C), RS113337668 (1:149525425 A>C), RS113721966 (1:149530673 A>C), RS11485704 (1:149483838 A>C), RS11488536 (1:149485303 C>T), RS11488537 (1:149480744 A>G,T), RS1156260337 (1:149487487 A>G), RS1156312702 (1:149555601 A>C)

Disease associations

OMIM: gene MIM:614006 | disease phenotypes: MIM:148300

GenCC curated gene-disease

Mondo (1): keratoconus (MONDO:0015486)

Orphanet (2): OBSOLETE: Keratoconus (Orphanet:156071), NON RARE IN EUROPE: Isolated keratoconus (Orphanet:2335)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000563	Keratoconus

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST007725_40	Serum uric acid levels	6.000000e-14
GCST007733_48	Serum uric acid levels	6.000000e-14
GCST007733_68	Serum uric acid levels	1.000000e-29

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004761	uric acid measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D007640	Keratoconus	C11.204.627

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

18 total (human), top 18 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
aristolochic acid I	increases expression	1
securinine	increases expression	1
sodium arsenite	decreases expression, increases abundance	1
zinc chromate	increases abundance, increases expression	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	increases methylation	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment	1
di-n-butylphosphoric acid	affects expression	1
chromium hexavalent ion	increases abundance, increases expression	1
abrine	increases expression	1
Arsenic	decreases expression, increases abundance	1
Benzo(a)pyrene	affects methylation	1
Cadmium	increases abundance, increases expression	1
Lipopolysaccharides	increases expression, affects response to substance, affects cotreatment	1
Methapyrilene	increases methylation	1
Tretinoin	increases expression	1
Aflatoxin B1	increases methylation	1
Cadmium Chloride	increases abundance, increases expression	1

Clinical trials (associated diseases)

279 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT01485211	PHASE4	COMPLETED	Corneal Thickness Changes During Corneal Collagen Cross-linking With Ultraviolet-A Irradiation and Riboflavin
NCT02119039	PHASE4	COMPLETED	Effect of CACICOL20 on Corneal Epithelial Healing After Cross-linking in Patients With Keratoconus
NCT03245853	PHASE4	COMPLETED	Epi-On Corneal Crosslinking for Keratoconus
NCT03429569	PHASE4	UNKNOWN	Cross-Linking ACcéléré Iontophorèse Confocal kératocONE
NCT04427956	PHASE4	COMPLETED	Corneal Crosslinking Treatment Study
NCT07474870	PHASE4	NOT_YET_RECRUITING	Outcomes of CTAK Surgery
NCT00371202	PHASE3	UNKNOWN	Comparison of Penetrating Keratoplasty and Deep Lamellar Keratoplasty With the Big Bubble Technique for Keratoconus
NCT00647699	PHASE3	COMPLETED	Corneal Collagen Cross-linking for Progressive Keratoconus
NCT00815256	PHASE3	UNKNOWN	Safety and Effectiveness of Collagen Cross Linking in Progressive Mild and Moderate Keratoconus
NCT00887900	PHASE3	COMPLETED	Deep Anterior Lamellar Keratoplasty (DALK)
NCT01112072	PHASE3	UNKNOWN	Corneal Collagen Crosslinking and Intacs for Keratoconus and Ectasia
NCT01152541	PHASE3	UNKNOWN	Corneal Collagen Crosslinking for Progressive Keratoconus and Ectasia Using Riboflavin/Dextran and Hypotonic Riboflavin
NCT01190306	PHASE3	TERMINATED	Safety Study of the VEGA UV-A System to Treat Keratoconus
NCT01344187	PHASE3	COMPLETED	Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus
NCT01459679	PHASE3	TERMINATED	Safety & Efficacy of Corneal Collagen Cross-Linking in Eyes With Keratoconus or Corneal Ectasia After Refractive Surgery
NCT01464268	PHASE3	UNKNOWN	Transepithelial Corneal Collagen Crosslinking for Keratoconus and Corneal Ectasia
NCT01604135	PHASE3	ACTIVE_NOT_RECRUITING	Collagen Crosslinking for Keratoconus - a Randomized Controlled Clinical Trial
NCT01643226	PHASE3	COMPLETED	Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus
NCT01672814	PHASE3	COMPLETED	Microwave Treatment and Corneal Collagen Crosslinking for Keratoconus
NCT01682993	PHASE3	TERMINATED	Corneal Cross Linking and Topography Guided Excimer Laser Treatment
NCT01972854	PHASE3	TERMINATED	Safety and Efficacy of Corneal Collagen Cross-Linking in Eyes With Keratoconus
NCT02613780	PHASE3	UNKNOWN	Refractive Treatment of Early Keratoconus
NCT02638376	PHASE3	UNKNOWN	Evaluating the Safety and Efficacy of the KXL System for Corneal Collagen Cross-Linking in Eyes Having Keratoconus
NCT03080077	PHASE3	UNKNOWN	Safety and Effectiveness of Corneal Crosslinking (CXL): Keratoconus and Post-Refractive Ectasia
NCT03187912	PHASE3	COMPLETED	Accelerated Corneal Cross-linking With Different Riboflavin Solutions
NCT03442751	PHASE3	COMPLETED	Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus
NCT03858036	PHASE3	UNKNOWN	Corneal Collagen Cross-Linking (CXL) Performed With Epi-ON Versus Epi-OFF in Eyes With Keratoconus and Other Corneal Ectatic Disorders
NCT04897503	PHASE3	UNKNOWN	Corneal Collagen Crosslinking for Keratoconus and Ectasia Using Riboflavin/Dextran or Riboflavin/Methylcellulose
NCT04905108	PHASE3	UNKNOWN	Transepithelial (Epi-on) Corneal Collagen Crosslinking to Treat Keratoconus and Corneal Ectasia
NCT05027295	PHASE3	UNKNOWN	Accelerated Corneal Collagen Crosslinking for Keratoconus and Ectasia Using Pulse or Continuous UV-A Light
NCT06100939	PHASE3	ACTIVE_NOT_RECRUITING	Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus
NCT06100952	PHASE3	ACTIVE_NOT_RECRUITING	Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age with Keratoconus
NCT06450470	PHASE3	RECRUITING	Use of a Freeze-dried Amniotic Membrane Post Crosslinking in Subjects With Progressive Keratoconus
NCT06601101	PHASE3	RECRUITING	Effects of Topical Insulin on Corneal Epithelium Healing After Corneal Crosslinking in Patients With Keratoconus
NCT07124910	PHASE3	RECRUITING	Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases
NCT07135167	PHASE3	RECRUITING	Compassionate Use Study of Epi-ON Corneal Collagen Crosslinking Performed Using UVA Exposure on Eyes With Ectatic Corneal Diseases for Subjects With Down Syndrome
NCT00409955	PHASE2	COMPLETED	Lamellar Transplant With Lyophilized Corneas
NCT00925327	PHASE2	UNKNOWN	Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking for Compassionate Treatment in Pediatric Patients With Progressive Keratoconus
NCT01143389	PHASE2	COMPLETED	Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia
NCT01181219	PHASE2	COMPLETED	Transepithelial Corneal Collagen Cross-linking (CXL) in Treatment of Keratoconus